CAS: 153-00-4; (5S,8R,9S,10S,13S,14S,17S)-17-Hydroxy-1,10,13-Trimethyl-4,5,6,7,8,9,11,12,14,15,16,17-Dodecahydrocyclopenta[a]Phenanthren-3-One

该化合物是一种源自二氢苯酯酮(DHT)的代谢类类类固醇,其特点是其低温和中度的代谢特性,使其在运动员和健美者中流行,以保持肌肉和增强肌肉,而无需大量保留水; 甲基甲醇以口服和注射两种形式提供,其乙醇变异为口服; 其化学结构在第一和第二碳原子之间有双倍的结合,有助于其稳定性和抗代谢破裂; 甲基甲醇经常用于切割周期,以帮助保持精瘦肌肉质量,同时减少体脂肪; 与其他代谢类固醇相比,其副作用风险相对较低,但潜在的不利影响仍然可能发生,包括肝毒性过量口服和荷尔蒙不平衡. 由于其代谢特性,甲醇素在许多国家被归类为受控物质,因此在竞争体育中被各种监管机构禁止使用.

结构式图片

上下游产品

3-Aethylendioxy-1-methylen-5α-androstanol-(17β)1β-Methyl-4,5α-dihydro-testosteron (17β-Hydroxy-1β-methyl-5α-androstan-3-on) mesterolone atamestane -5α-androst-1-en-3-one17β-acetyloxy-1,4α-dimethyl-2-(phenylthio)methyl-5α-androst-1-en-3-one

合成工艺路线路线简述

    📜美替诺龙庚酸酯置于cunninghamella Blakesleeana体系中,用 甲醇 用作溶剂,化学反应 288.0H,反应生成美替诺龙
    参考文献:Aspergillus Niger-Mediated Biotransformation Of Methenolone Enanthate,And Immunomodulatory Activity Of Its Transformed Products
    标题:Aspergillus Niger-Mediated Biotransformation Of Methenolone Enanthate,And Immunomodulatory Activity Of Its Transformed Products
    摘要:Two Fungal Cultures Aspergillus Niger And Cunninghamella Blakesleeana Were Used For The Biotransformation Of Methenolone Enanthate (1). Biotransformation With A. Niger Led To The Synthesis Of Three New (2-4),And Three Known (5-7) Metabolites,While Fermentation With C. Blakesleeana Yielded Metabolite 6. Substrate 1 And The Resulting Metabolites Were Evaluated For Their Immunomodulatory Activities. Substrate 1 Was Found To Be Inactive,While Metabolites 2 And 3 Showed A Potent Inhibition Of Ros Generation By Whole Blood (Ic50= 8.60 And 7.05 Mu G/ml),As Well As From Isolated Polymorphonuclear Leukocytes (Pmns) (Ic50= 14.0 And 4.70 Mu G/ml),Respectively. Moreover,Compound 3 (34.21%) Moderately Inhibited The Production Of Tnf-Alpha,Whereas 2 (88.63%) Showed A Potent Inhibition Of Tnf-Alpha Produced By The Thp-1 Cells. These Activities Indicated Immunomodulatory Potential Of Compounds 2 And 3. All Products Were Found To Be Non-Toxic To 3T3 Mouse Fibroblast Cells. (C) 2016 Elsevier Inc. All Rights Reserved.
    Doi:10.1016/j.Steroids.2016.04.007

    海关参考信息

    专利信息


    专利号:US-2013035307-A1
    优先权日:2010-01-26
    标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
    发明人:PRESTWICH GLENN D; KENNEDY THOMAS P
    权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
    摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.

    专利号:US-2014274978-A1
    优先权日:2013-03-15
    标题 :Phytosterol spirostane and spirostene derivatives having a wide variety of utilities in humans and other animals
    发明人:FASCIOLA ANDRE ARMEL
    权利人:FASCIOLA ANDRE ARMEL
    摘要:The present invention utilizes phytosterol, phytoecdysteroid, sapogenin, triterpene, terpene, spirostane, spirostene and androstene derivative compounds to provide a wide variety of utilities to humans and other animals. The compounds and methods provide numerous and wide-ranging benefits including biochemical and constructive metabolic benefits including increases in protein synthesis and synthesis efficiency, ergogenic, adaptogenic, cosmetic and medicinal skin agents and veterinary utilities. The compounds provide agents that increase physical endurance and work output, act as a general tonic for increasing health and vigor, increase sleep time and sleep efficiency and act as rejuvenating agents to reverse the effects of fatigue and stress. Novel utilities for pet, farm, zoo and companion animals are also provided.

    专利号:US-2025281509-A1
    优先权日:2021-04-26
    标 题 :Sequential hormone therapy to improve survival and enhance response to immune therapy in men with prostate cancer
    发明人:DENMEADE SAMUEL R; ISAACS JOHN T; ANTONARAKIS EMMANUEL S; KACHHAP SUSHANT; MARKOWSKI MARK CHRISTOPHER
    权利人:UNIV JOHNS HOPKINS
    摘要:Disclosed are methods for treating men with castrate resistant prostate cancer with a sufficient dose of testosterone to achieve supraphysiologic serum levels of testosterone in sequence with androgen ablative treatment or androgen synthesis inhibitors for one or more cycles until evidence of radiographic progression, at which point the subject will receive immune checkpoint blockade therapy.

    专利号:US-9023384-B2
    优先权日:2004-11-02
    标题:Liposome and method for injecting substance to cell using this liposome
    发明人:MORITA IKUO; AKIYOSHI KAZUNARI; NOMURA SHINICHIRO
    权利人:MORITA IKUO; AKIYOSHI KAZUNARI; NOMURA SHINICHIRO; UNIV TOKYO MEDICAL & DENTAL; DAINIPPON PRINTING CO LTD
    摘要:It is intended to efficiently inject into a target cell, a substance charged within a liposome. The present inventors have found that connexin synthesized within a liposome is introduced as connexon having a gap junction function into the liposome membrane. Specifically, the liposome according to the present invention is a liposome in which connexon composed of connexin synthesized by an in-vitro protein synthesis system is incorporated in a state of having a gap junction function.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    摘要:21 CFR Sections 1308.11-1308.15
    摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198
    摘要:Papanayotou PH. Treatment of recurrent aphthous ulcers with anabolic drugs. Preliminary report. J Oral Med. 1972 Oct;27(4):113–4.
    摘要:Hyman M. Anabolic therapy of recurrent aphthous ulcers. J Oral Med. 1972 Oct;27(4):115.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知